A citation-based method for searching scientific literature

T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
Times Cited: 226







List of co-cited articles
556 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
243
39

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
145
31


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
302
30

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
227
29

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
279
28


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
239
26


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
242
22

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
149
22


Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
121
19

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
103
18


Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
80
21

Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
74
22

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
412
15

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
75
20





A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
63
22

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
186
13





Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Ildiko Lingvay, Federico Pérez Manghi, Pedro García-Hernández, Paul Norwood, Lucine Lehmann, Mads Jeppe Tarp-Johansen, John B Buse. JAMA 2016
123
12


The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
Svend Havelund, Anne Plum, Ulla Ribel, Ib Jonassen, Aage Vølund, Jan Markussen, Peter Kurtzhals. Pharm Res 2004
273
11

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
822
11


Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
11


Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
11

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
117
11

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
A Steinstraesser, R Schmidt, K Bergmann, R Dahmen, R H A Becker. Diabetes Obes Metab 2014
64
17


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
11

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
John B Buse, Tina Vilsbøll, Jerry Thurman, Thomas C Blevins, Irene H Langbakke, Susanne G Bøttcher, Helena W Rodbard. Diabetes Care 2014
170
11




Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Gregory R Fulcher, Jens Sandahl Christiansen, Ganapathi Bantwal, Miroslawa Polaszewska-Muszynska, Henriette Mersebach, Thomas H Andersen, Leo K Niskanen. Diabetes Care 2014
69
14

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
Tim Heise, Stefan Korsatko, Leszek Nosek, Hans Veit Coester, Sigrid Deller, Carsten Roepstorff, Stine Segel, Rahul Kapur, Hanne Haahr, Marcus Hompesch. J Diabetes 2016
31
32

Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).
Athena Philis-Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco, Jeffrey Rothman. Adv Ther 2013
33
30



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.